We report on the evaluation of the second-generation assay for cardiac troponin T (cTnT) on the Enzymun ® system. This new assay is completely specific for the cardiac isoform of TnT, utilizing two cardiospecific monoclonal antibodies. The assay time is reduced to 45 min. The interassay precision shows a median CV of 5.5%; 20% interassay CV was found between 0.05 and 0.1 g/L. The cardiosensitivity of the secondgeneration cTnT assay in patients with ischemic myocardial injury appears equivalent when compared with the first-generation assay. We found no falsely positive results in patients with skeletal muscle damage including multitraumas, surgery patients, and marathon runners who showed highly increased values with the unspecific first-generation assay. In Duchenne disease cTnT was still increased, but to a much lower extent. cTnT remains increased in renal failure, but to a lesser degree than with the firstgeneration assay. The cause of this increase remains unclear. Although a cross-reactivity of skeletal muscle TnT in the second-generation assay could be excluded by our findings, minor myocardial damage or expression of the cardiac isoform of TnT in regenerating muscles cannot be ruled out in those cases with apparently falsely increased cTnT values. The secondgeneration cTnT assay is a step forward in the combination of cardiosensitivity and cardiospecificity in biochemical markers for diagnosis of heart disease.
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Cardiac troponin T (cTnT) is a polypeptide subunit of the myofibrillar regulatory troponin complex of striated and heart muscle and is expressed in different isoforms in skeletal muscle and myocardium [1] . 9 The major part of the troponin complex is structurally bound to the contractile elements of the myocyte [2] . After ischemic myocardial damage the release of the cytosolic part of cTnT causes an initial peak similar to those of cytosolic markers such as creatine kinase (CK) and CK-MB isoenzyme. However, subsequent release of the structurally bound part of cTnT leads to a protracted cTnT increase that may last for days or weeks depending on the size of the infarcted area [3] . Of all patients with unstable angina, 30 -40% show increases in cTnT Ͼ0.10 g/L, indicating minor myocardial damage (MMD). Several studies [4 -8] have documented that MMD patients have the same short-term prognosis as do patients with infarctions according to the classical WHO criteria.
Although the clinical usefulness of the high diagnostic sensitivity of cTnT in cardiac diseases is well established, the diagnostic specificity of cTnT has been doubted by various findings. The first version of the cTnT assay (TnT 1) had a cross-reaction of at least 2% with skeletal muscle [9] . This did not interfere with the diagnostic specificity in the coronary care unit (CCU) in the absence of skeletal muscle damage, but obviously made the results difficult to interpret in traumatized patients. cTnT increases have been observed in certain types of myositis such as sclerodermatomyositis and Duchenne disease [10] , and in patients with chronic or acute renal failure [11] [12] [13] [14] without evidence of ischemic myocardial injury with the TnT 1 assay. Even the cardiospecificity of the analyte itself has been questioned by the observation that cTnT determined with the TnT 1 assay may be reexpressed in regenerating skeletal muscle [15] . Whether these findings are due to the described cross-reactivity with skeletal muscle TnT, expression of the cardiac isoform of TnT in diseased muscles, or to MMD not detectable with other clinical methods or biochemical markers is as yet unclear. To assure the analytical cardiospecificity, an improved "second-generation" assay with a different antibody panel, Enzymun ® TnT (TnT 2), has been developed [16] .
The present multicenter study was carried out to evaluate the cardiospecific TnT 2 assay and compare it with TnT 1 in different patient groups.
Materials and Methods
Testing sites. Eight hospitals (Table 1 ) participated, following a general protocol with some individual deviations described in the text.
analytical methods
The TnT 1 assay was performed with two different lots, ELISA TnT lots 186190 and 186145. The TnT 2 assay (Enzymun Troponin T) has two monoclonal antibodies. A new cardiospecific monoclonal antibody (11-7) was developed to serve as the biotinylated capture antibody [16] , and the cardiospecific capture antibody of the TnT 1 assay [17] is now used as the signal antibody. The assay time has been reduced to 45 min on the ES system and the stability of the reagents and calibrators has been extended to 2 weeks (incubation solution) and 1 week at ϩ4°C, respectively. All measurements of cTnT were made with first-and second-generation assays on ES 300 or ES 700 analyzers (Boehringer Mannheim).
The evaluation was carried out with two lots, A and B. The calibrator values of lot A were reassigned after the completion of the study to guarantee comparable results of both lots.
Imprecision. Three control sera (controls A, B, and C) and different human serum pools were assayed for intraassay (20 samples/run) and interassay (each day up to 43 days) imprecision.
Analytical range and linearity. To determine the analytical sensitivity, all collaborating laboratories measured the zero calibrator supplied with the reagent kit in 20 replicates. Mean ϩ 2SD of the signal were calculated and read of the actual calibration curve to give the lower detection limit. Linearity was investigated by serial dilution of different sera containing high amounts of cTnT. The measured values in terms of recovery were plotted against the expected cTnT values derived from linear regression analysis.
Stability of cTnT. Short-term and long-term stability studies were performed. We aliquoted and tested 10 serum samples from patients with cTnT values between 0.11 and 15.34 g/L. TnT results in fresh serum were compared with the results after different times of storage up to 3 months at Ϫ20°C. We also tested the influence of repeated freezing and thawing.
Collection tubes. To study the influence of different serum and plasma collection tubes, we collected from five patients different serum and plasma specimens: white (without anticoagulation), brown (without anticoagulation, with gel), red (K 2 EDTA), blue (NH 4 -heparin), green (sodium citrate), yellow (Na-fluoride) tubes, all from Sarstedt; serum with gel barrier from Terumo and from Becton Dickinson (type SST). Also, at two sites a more significant number of paired values for heparin plasma and serum (n ϭ 46 and n ϭ 18) and on one site for citrate plasma and serum (n ϭ 19) was collected (all tubes from Sarstedt).
Method comparison. We compared the TnT 1 and the TnT 2 assays using 1084 serum specimens from randomly selected patients with increased CK activity. For each different testing site and for the combined groups, regression analysis was performed and comparisons were made. 
clinical studies
We compared TnT 1 and TnT 2 in several clinical populations to look for differences in the diagnostic sensitivity and specificity. Subjects. We compared the diagnostic sensitivity of the two assays in serum samples from patients with ischemic heart diseases: 341 serum samples from patients with acute myocardial infarction (AMI), 130 from patients with unstable angina pectoris, and 51 from patients undergoing percutaneous transluminary coronary angioplasty (PTCA). To investigate possible unspecificity in patients with skeletal muscle disease or renal diseases, we examined 33 serum samples from patients with Duchenne disease, serum samples before and after a race from 42 marathon runners, and serum samples from 30 patients with end-stage renal failure undergoing chronic hemodialysis. Furthermore, we compared TnT 1 and TnT 2 results in the following individual cases: a case with extensive hypoxic skeletal muscle injury and increased total CK, a rhabdomyolysis in hereditary myoglobulinuria, a progressing dermatomyositis, a pressure-induced skeletal muscle injury, and a decubitus case.
Results

analytical performance
Imprecision. The results of intra-and interassay imprecision are summarized in Table 2 . CVs between 1.4% and 5.9% for intraassay imprecision and between 2.4% and 9.5% for interassay imprecision were obtained over the whole measuring range and the highest CVs for the control serum in the range of the cutoff.
Analytical sensitivity. The lower detection limit was calculated to be 0.01 g/L at evaluation sites 2 and 5 and 0.02 g/L at site 7. A functional sensitivity of 20% interassay CV was estimated between 0.05 and 0.1 g/L.
Linearity. Recovery of the expected concentration for one typical dilution experiment is shown in Fig. 1 . The assay seems sufficiently linear over the whole measuring range.
Interfering substances. Serial dilutions of sera containing 0.21 and 0.32 g/L cTnT were diluted with sera containing possible interfering substances. No interference was seen (Ϯ10%) for hemoglobin up to 0.62 mmol/L, bilirubin up to 1128.6 mol/L, and lipemia up to 17.1 mmol/L triacylglycerol.
Analyte stability. cTnT values in fresh samples and in samples stored at room temperature up to 24 h, at ϩ4°C over 1 week, and at Ϫ20°C for 3 months show no significant deviation (evaluator 7). A regression analysis for the 10 samples gives the following equations according to Passing/Bablok (x ϭ fresh, y ϭ stored):
1 day room temperature: y ϭ 0.89x ϩ 0.02 1 week ϩ4°C: y ϭ 0.95x ϩ 0.01 3 months Ϫ20°C: y ϭ 0.91x ϩ 0.01 At a different evaluation site no loss of cTnT concen- and no significant differences for citrate plasma (after volume correction) compared with serum (x ϭ plasma, y ϭ serum): Lab. 2: Heparin plasma y ϭ 1.10x ϩ 0.01, r ϭ 0.99 (n ϭ 18) Lab. 5: Citrate plasma y ϭ 1.01x ϩ 0, r ϭ 1.00 (n ϭ 19) Lab. 7: Heparin plasma y ϭ 1.07x ϩ 0, r ϭ 0.96 (n ϭ 46)
Analytical comparison with TnT 1. Results are summarized in Table 3 . The slopes of the separate evaluation of the lower range deviate obviously from those of the whole range. This deviation is pronounced for lot A with preliminary standardization and reduced for lot B with final standardization. The relation between TnT 1 and TnT 2 can be influenced by the selection of the sample material as can be seen in the slope differences of the individual testing sites, which used patient samples with various clinical backgrounds. Fig. 2 shows a characteristic example for the relation between the first-and secondgeneration assays in the whole analytical range (Fig. 2a) and in the lower range (Fig. 2b) based on the final standardization lot B with samples preferably from a CCU. A considerable number of sera show cTnT values Ͻ0.1 g/L with TnT 2 and Ͼ0.1 g/L with TnT 1, thus indicating some possible unspecificity of the first-generation assay. Marathon runners. As shown in Fig. 3 , no cross-reactivity with skeletal muscle isoforms of TnT in marathon runners can be detected with TnT 2.
Muscular dystrophy.
In patients with Duchenne disease, increased values are significantly reduced with TnT 2 (Fig. 4) . If related to a decision concentration of 0.2 g/L, which may be taken for safety reasons in situations Individual cases with potential cross-reaction of skeletal muscle troponin T. One case of pure skeletal muscle damage caused by two severe epileptic seizures showed a 12-fold increase of total CK activity and 33-fold of TnT 1, but no increase at all of TnT 2, confirmed by no clinical or electrocardiogram (ECG) signs of myocardial damage (Fig. 5a) . In a case with severe hypoxic skeletal muscle damage after embolism in the foot, we found an increase of total CK and TnT 1, and a late increase of CK-MB mass; however, we saw a TnT 2 concentration at the detection limit in all examined samples (Fig. 5 b) . A case of hereditary myoglobulinuria with severe rhabdomyolysis, 90-fold increased myoglobin, 200-fold increased total CK activity, 13-fold increased CK-MB mass, and 1.3-fold increased creatinine showed a TnT 2 value of 0.07 g/L.
A case of prednisolone-treated progressing dermatomyositis with 95-fold increased total CK activity and sevenfold increased CK-MB mass showed a TnT 2 value of 0.02 g/L. A decubitus case with 125-fold increased total CK and increasing creatinine showed a TnT 2 value of 0.02 g/L.
Patients with renal insufficiency. Only small differences between TnT 1 and TnT 2 were seen in patients with renal failure (Fig. 6 ). With Patients with ischemic heart disease. A good correlation between TnT 1 and TnT 2 was found in patients with AMI, unstable angina pectoris, or undergoing PTCA (Table 3 ). The differences in the slopes of the regression analysis can be explained mainly by standardization effects as mentioned above.
Discussion
The second-generation cTnT assay is characterized by a lower imprecision and detection limit, reduced assay time, and an absolute specificity for the cardiac isoform of TnT. The new assay remains uninfluenced by various preanalytical conditions such as different anticoagulants or serum tubes with gel barrier. This is an improvement in comparison with the first-generation assay for which Wu et al. [18] found an average deviation of Ͼ5% for all plasma samples with the exception of heparin plasma compared with serum. On the basis of the investigation of ϳ5000 noncardiac diseased and healthy individuals, Mü ller-Bardorff et al. [16] reported that the cutoff value for the clinical decision of a myocardial damage can be maintained at 0.1 g/L as already specified for the first-generation assay. However, this value seems to have an increased reliability because several unspecific increases can be excluded.
The crucial criteria for the assessment of TnT 2 compared with TnT 1 are the cardiosensitivity and cardiospecificity. To investigate sensitivity, we compared both assays in patients with ischemic myocardial injury, AMI, or unstable angina pectoris and undergoing PTCA. In all patients, no significant differences between the two assays were observed. These findings show that both assays have the same sensitivity in patients with ischemic myocardial injury, give the same clinical information, and are inter- convertible with each other without loss of evidence in longitudinal observations. The cardiospecificity has to be shown in very different clinical situations. If the clinical background of a patient is rather unclear or characterized by multimorbidity, clinical decision making should be based on a raised cTnT cutoff value of 0.2 g/L. For the first-generation cTnT assay, Hafner et al. [11] , Bhayana et al. [12] , and Li et al. [13] reported increased cTnT values without evidence of ischemic myocardial damage in patients with end-stage renal failure undergoing maintenance hemodialysis. Baum et al. [14] demonstrated increased first-generation assay cTnT values also in patients with acute renal failure, with sepsis, and after liver transplantation.
Regarding the results in 30 patients with end-stage renal failure undergoing chronic hemodialysis in the present study, the portion of increased values obtained with the second-generation assay is only slightly reduced from 37% to 20%-if related to the decision concentration of 0.2 g/L-in comparison with the first-generation assay. A more significant reduction of pathologically increased values with TnT 2 can be observed in the patient group of Duchenne disease, and the eight pathological cTnT concentrations of 33 samples are only marginally above the limit of 0.2 g/L. A more distinct improvement in the cardiospecificity of TnT 2 is found in the patient groups with typical skeletal muscle damage. An assessment of specificity can be based here on the usual "cardiac" cutoff of 0.1 g/L. Twenty of 42 marathon runners who showed increased cTnT values after a race with TnT 1 had no increased values at all with TnT 2. In the case of purely skeletal muscle damage (Fig. 5) , assuming a 2% crossreactivity of TnT 1 with skeletal muscle TnT and a detection limit of 0.02 g/L for TnT 1, peak skeletal muscle TnT would have been 165 g/L, and correspondingly cross-reactivity of TnT 2 must be Ͻ0.02/ 165 ϭ 0.01%. Thus, for all practical purposes, interference by skeletal muscle TnT cross-reactivity can be excluded for the second-generation assay. The results of the first-generation assay are explainable, as this assay shows cross-reactivity of at least 2% with the skeletal muscle isoform of TnT [9] due to the fact that only one cardiospecific monoclonal antibody has been used in this assay. In the new assay the capture and label antibodies are both cardiospecific anti-cTnT antibodies without cross-reactivity with the skeletal muscle isoform. This was confirmed with Western blot analysis [16] . Increases therefore cannot simply be explained by possible cross-reactivity with the skeletal muscle isoform of TnT.
The increased cTnT values in patients with end-stage renal failure and Duchenne disease therefore indicate either possible minor myocardial injury not detectable with "classical" biochemical markers for the detection of myocardial damage or expression of the cardiac isoform of TnT in diseased muscles. As a history of ischemic myocardial damage is expected to occur more often in hemodialysis patients [19, 20] , minor ischemic myocardial damage without clinical signs cannot be ruled out. MMD in patients with Duchenne disease can also not be ruled out with standard criteria. These two possibilities as a source of cTnT must be investigated in further studies. Up to that point, misinterpretation can be avoided by the simple means of determining cTnT in two samples, e.g., with 6-h intervals. Myocardial damage will cause a significant rapid increase; this does not occur by purely renal failure or muscular disease.
In conclusion, this modified assay for cTnT measurement is superior over the first-generation assay, with an increased specificity and a reduced turnaround time, but without a change in sensitivity in the diagnosis of AMI or MMD. 
